Jump to content

Tropicamide/phenylephrine

From Wikipedia, the free encyclopedia

Tropicamide/phenylephrine
Combination of
TropicamideAnticholinergic
PhenylephrineAlpha-1 adrenergic receptor agonist
Clinical data
Trade namesMydcombi
Routes of
administration
Topical,ophthalmic
ATC code
Legal status
Legal status

Tropicamide/phenylephrine,sold under the brand nameMydcombiis afixed dose combinationof tropicamide and phenylephrine used to dilate the eyes (mydriasis).[1]It contains, tropicamide, ananticholinergic,and phenylephrine, as the hydrochloride, analpha-1 adrenergic receptor agonist.[1]It is sprayed into the eyes.[1]

It was approved for medical use in the United States in May 2023.[2][3]

Medical uses

[edit]

Tropicamide/phenylephrine is used for the short-term dilation of the pupils.[1]

References

[edit]
  1. ^abcdehttps://mydcombi.com/wp-content/uploads/2023/05/MydCombi-PI-05072023.pdf
  2. ^"Mydcombi: FDA-Approved Drugs".U.S.Food and Drug Administration(FDA).Retrieved8 May2023.
  3. ^"Eyenovia Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company's Proprietary Optejet Device Platform".Eyenovia.8 May 2023.Retrieved8 May2023.
[edit]
  • Clinical trial numberNCT03751631for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-1)" atClinicalTrials.gov
  • Clinical trial numberNCT03751098for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-2)" atClinicalTrials.gov